Poseida Therapeutics, Inc. (PSTX)

2.6400 -0.0300 (-1.12%) At close: 04:00PM EST

Poseida Therapeutics, Inc.

9390 Towne Centre Drive
Suite 200
San Diego, CA 92121
United States
858 779 3100
https://poseida.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 327

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Mark J. Gergen J.D.	President, CEO & Chairman	920.74k	N/A	1963
Mr. Harry J. Leonhardt Esq., J.D.	General Counsel, Chief Compliance Officer & Corporate Secretary	630.23k	N/A	1957
Mr. Brent Warner	President of Gene Therapy	835.93k	N/A	1984
Ms. Johanna M. Mylet CPA	Chief Financial Officer	N/A	N/A	1987
Mr. Loren Wagner	Senior Vice President of Global Operations	N/A	N/A	N/A
Ms. Kristin Martin	Chief People & Administration Officer	N/A	N/A	N/A
Sarah Thailing	Senior Director of Corporate Communications & IR	N/A	N/A	N/A
Dr. Devon J. Shedlock Ph.D.	Chief Scientific Officer of Cell Therapy	N/A	N/A	N/A
Ms. Lisa Portale	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A
Dr. Jeffrey W. Winkelman J.D., Ph.D.	Senior VP & Chief Patent Counsel	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-101, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101, a liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; and P-PAH-101, a liver-directed gene therapy for the in vivo treatment of phenylketonuria. Poseida Therapeutics, Inc. has a research collaboration and license agreement with Takeda Pharmaceuticals USA, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.

Corporate governance

Poseida Therapeutics, Inc.’s ISS governance QualityScore as of 1 December 2023 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.